Portal de Periódicos da CAPES

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

2018; National Comprehensive Cancer; Volume: 16; Issue: 5S Linguagem: Inglês

10.6004/jnccn.2018.0047

1540-1413

John A. Thompson,

Colorectal Cancer Treatments and Studies

Immune checkpoint inhibitors (ICIs) are now FDA-approved for the treatment of 8 different cancers, and more approvals are likely, including use of these drugs in combinations. Although ICIs represent a true advance in cancer care, they can cause a range of immune-related adverse events. As more experience with ICIs is gained, more information is becoming available on immunotoxicity and optimal management. Physicians and patients need to be educated about potential adverse events and management of ICI-associated toxicity. In recognition of the need for better information, NCCN in collaboration with ASCO has developed the first set of NCCN Guidelines for Management of Immunotherapy-Related Toxicities.